Health IT Analytics April 12, 2021
Using genetic data, researchers found that drugs targeting two proteins could keep COVID-19 patients from being hospitalized.
An analysis of genetic data indicates that leaders should prioritize clinical trials of two proteins – IFNAR2 and ACE2 – to better treat COVID-19 in its early stages.
In a study published in Nature Medicine, researchers used genetic data to identify drugs that can be repurposed for treating COVID-19. In the past, researchers have used large-scale human genetic studies to inform drug development programs, with some research identifying COVID-19 drug targets.
“The reason we used human genetics is as follows,” said Juan P. Casas, a physician epidemiologist at the Veterans Affairs Boston Healthcare System and leader of the study.
“Given that more than...
Today's Sponsors
Today's Sponsor